Cargando…
Treatment options for acute myeloid leukemia patients aged <60 years
Treatment of acute myeloid leukemia (AML) has changed over the last few years, after the discovery of new drugs selectively targeting AML blasts. Although 3/7 remains the standard of care for most AML patients, several new targeted agents (such as FLT3 inhibitors, CPX-351, gemtuzumab ozogamicin, BCL...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581198/ https://www.ncbi.nlm.nih.gov/pubmed/36276074 http://dx.doi.org/10.3389/fonc.2022.897220 |
_version_ | 1784812565681930240 |
---|---|
author | Visani, Giuseppe Chiarucci, Martina Paolasini, Sara Loscocco, Federica Isidori, Alessandro |
author_facet | Visani, Giuseppe Chiarucci, Martina Paolasini, Sara Loscocco, Federica Isidori, Alessandro |
author_sort | Visani, Giuseppe |
collection | PubMed |
description | Treatment of acute myeloid leukemia (AML) has changed over the last few years, after the discovery of new drugs selectively targeting AML blasts. Although 3/7 remains the standard of care for most AML patients, several new targeted agents (such as FLT3 inhibitors, CPX-351, gemtuzumab ozogamicin, BCL-2 inhibitor, and oral azacitidine), either as single agents or combined with standard chemotherapy, are approaching clinical practice, starting a new era in AML management. Moreover, emerging evidence has demonstrated that high-risk AML patients might benefit from both allogeneic stem cell transplant and maintenance therapy, providing new opportunities, as well as new challenges, for treating clinicians. In this review, we summarize available data on first-line therapy in young AML patients focusing on targeted therapies, integrating established practice with new evidence, in the effort to outline the contours of a new therapeutic paradigm, that of a “total therapy”, which goes beyond obtaining complete remission. |
format | Online Article Text |
id | pubmed-9581198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95811982022-10-20 Treatment options for acute myeloid leukemia patients aged <60 years Visani, Giuseppe Chiarucci, Martina Paolasini, Sara Loscocco, Federica Isidori, Alessandro Front Oncol Oncology Treatment of acute myeloid leukemia (AML) has changed over the last few years, after the discovery of new drugs selectively targeting AML blasts. Although 3/7 remains the standard of care for most AML patients, several new targeted agents (such as FLT3 inhibitors, CPX-351, gemtuzumab ozogamicin, BCL-2 inhibitor, and oral azacitidine), either as single agents or combined with standard chemotherapy, are approaching clinical practice, starting a new era in AML management. Moreover, emerging evidence has demonstrated that high-risk AML patients might benefit from both allogeneic stem cell transplant and maintenance therapy, providing new opportunities, as well as new challenges, for treating clinicians. In this review, we summarize available data on first-line therapy in young AML patients focusing on targeted therapies, integrating established practice with new evidence, in the effort to outline the contours of a new therapeutic paradigm, that of a “total therapy”, which goes beyond obtaining complete remission. Frontiers Media S.A. 2022-10-05 /pmc/articles/PMC9581198/ /pubmed/36276074 http://dx.doi.org/10.3389/fonc.2022.897220 Text en Copyright © 2022 Visani, Chiarucci, Paolasini, Loscocco and Isidori https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Visani, Giuseppe Chiarucci, Martina Paolasini, Sara Loscocco, Federica Isidori, Alessandro Treatment options for acute myeloid leukemia patients aged <60 years |
title | Treatment options for acute myeloid leukemia patients aged <60 years |
title_full | Treatment options for acute myeloid leukemia patients aged <60 years |
title_fullStr | Treatment options for acute myeloid leukemia patients aged <60 years |
title_full_unstemmed | Treatment options for acute myeloid leukemia patients aged <60 years |
title_short | Treatment options for acute myeloid leukemia patients aged <60 years |
title_sort | treatment options for acute myeloid leukemia patients aged <60 years |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581198/ https://www.ncbi.nlm.nih.gov/pubmed/36276074 http://dx.doi.org/10.3389/fonc.2022.897220 |
work_keys_str_mv | AT visanigiuseppe treatmentoptionsforacutemyeloidleukemiapatientsaged60years AT chiaruccimartina treatmentoptionsforacutemyeloidleukemiapatientsaged60years AT paolasinisara treatmentoptionsforacutemyeloidleukemiapatientsaged60years AT loscoccofederica treatmentoptionsforacutemyeloidleukemiapatientsaged60years AT isidorialessandro treatmentoptionsforacutemyeloidleukemiapatientsaged60years |